NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis

Monte Rosa Therapeutics, Inc. (GLUE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GLUE

$11.22

−$0.14 (−1.23%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GLUE with… →

GLUE Key Statistics

As of Oct 21, 2026
Trading
Open
$11.38
Previous Close
$11.36
Day's Range
11.09–11.74
52-Week Range
8.94–25.77
Volume
1.07M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.37
Valuation
Market Cap
$957.22M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
33.32
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.75
Financials (FY)
Revenue (FY)
$123.67M+63.54%
Net Income (FY)
−$38.63M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
85.31M
1-Year Return
+17.00%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.39M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GLUE closed at $11.22, +17.00% over 1 year.

Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalization of $957.22M.

In fiscal 2025, GLUE reported revenue of $123.67M.

GLUE Stock Return by Calendar Year

Monte Rosa Therapeutics, Inc. (GLUE) return since Jun 2021: what $10,000 became

1 year
$10,000 $11,700
+17.00%
5 years
$10,000 $4,502
−54.98%
Since Jun 2021
$10,000 $5,297
−47.03%

If you had invested $10,000 in Monte Rosa Therapeutics, Inc. (GLUE) at the close on June 24, 2021, the earliest close on record here, it would have been worth $5,297 at the close on October 21, 2026: −47.03% in total, −11.25% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.44%
2025+125.94%
2024+22.83%
2023−25.76%
2022−62.73%
2021 (partial year)−3.59%

As of October 21, 2026.

GLUE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$123.67M−$38.63M−31.2%
2024$75.62M−$72.70M−96.1%
2023$0.00−$135.35M—
2022$0.00−$108.50M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$123.67M—−$54.21M−$38.63M−31.2%
2024$75.62M—−$81.11M−$72.70M−96.1%
2023$0.00—−$143.31M−$135.35M—
2022$0.00—−$112.38M−$108.50M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GLUE Valuation vs Biotechnology Median

Median of 608 stocks
MetricGLUEBiotechnology medianvs median
P/S ratio33.3213.30151% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Monte Rosa Therapeutics, Inc. (GLUE) carries a market capitalisation of $957.22M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 173.

The 52-week range on file runs from $8.94 to $25.77. GLUE last closed at $11.22 on October 21, 2026. That is −$0.14 (−1.23%) against the previous close. The latest close sits 25.46% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $123.67M. That is +63.54% against the prior fiscal year, when revenue was $75.62M. The same year closed with a net loss of $38.63M. Trailing earnings per share are −1.75.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $123.67M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 33.32 times revenue. On price-to-sales that is 150.56% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.37. Daily returns over the trailing 5 years annualize to a volatility of 100.51%. The trailing one-year total return is +17.00%. Measured over 5 years, that is −14.75% a year compounded.

Growth & Income

The record shows no dividend for GLUE.

Across the complete calendar years on file, 2025 returned +125.94% and 2022 returned −62.73%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is −28.44% year to date.

Peer Comparison

Monte Rosa Therapeutics, Inc. (GLUE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Monte Rosa Therapeutics, Inc. GLUE $957.22M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Monte Rosa Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Visit website →